Yeah - looks like an over-zealous school prefect approach!
I would have thought that a clarification - explaining that the study was financed by Lumos and that the public health savings did not constitute a potential revenue target (which was obvious anyway) - would have been sufficient. After all, the study, despite its funding, was undertaken by a reputable company and published in a peer-reviewed journal.
Retraction is overkill and appears to be the result of unwarranted 'bullying'.
Ann: Update on Economic Evaluation of FebriDx, page-6
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
0.001(3.33%) |
Mkt cap ! $14.92M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.2¢ | 3.0¢ | $59.53K | 1.912M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1117600 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 490000 | 4 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| LDX (ASX) Chart |